[go: up one dir, main page]

NO995812L - Metode og sammensetninger for administrering av taxaner oralt til pasienter - Google Patents

Metode og sammensetninger for administrering av taxaner oralt til pasienter

Info

Publication number
NO995812L
NO995812L NO995812A NO995812A NO995812L NO 995812 L NO995812 L NO 995812L NO 995812 A NO995812 A NO 995812A NO 995812 A NO995812 A NO 995812A NO 995812 L NO995812 L NO 995812L
Authority
NO
Norway
Prior art keywords
patients
administration
compositions
taxanes orally
taxanes
Prior art date
Application number
NO995812A
Other languages
English (en)
Other versions
NO995812D0 (no
Inventor
Samuel Broder
Kenneth L Duchin
Sami Selim
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of NO995812D0 publication Critical patent/NO995812D0/no
Publication of NO995812L publication Critical patent/NO995812L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO995812A 1997-05-27 1999-11-26 Metode og sammensetninger for administrering av taxaner oralt til pasienter NO995812L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27
PCT/US1998/007776 WO1998053811A1 (en) 1997-05-27 1998-04-22 Method and compositions for administering taxanes orally to human patients

Publications (2)

Publication Number Publication Date
NO995812D0 NO995812D0 (no) 1999-11-26
NO995812L true NO995812L (no) 2000-01-25

Family

ID=25341241

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995812A NO995812L (no) 1997-05-27 1999-11-26 Metode og sammensetninger for administrering av taxaner oralt til pasienter

Country Status (22)

Country Link
EP (1) EP0994706B1 (no)
JP (1) JP2002500667A (no)
KR (1) KR100615783B1 (no)
CN (2) CN1550231A (no)
AR (1) AR012731A1 (no)
AT (1) ATE308365T1 (no)
AU (1) AU7130098A (no)
BR (1) BR9809694A (no)
CA (1) CA2290446C (no)
CZ (1) CZ9904244A3 (no)
DE (1) DE69832173T2 (no)
DK (1) DK0994706T3 (no)
ES (1) ES2247690T3 (no)
HU (1) HUP0003546A3 (no)
IL (2) IL132992A0 (no)
NO (1) NO995812L (no)
PL (1) PL337064A1 (no)
RU (1) RU2205005C2 (no)
SK (1) SK157599A3 (no)
UA (1) UA74767C2 (no)
WO (1) WO1998053811A1 (no)
ZA (1) ZA984268B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
ATE219363T1 (de) * 1997-06-20 2002-07-15 Baker Norton Pharma Lösliche prodrugs von paclitaxel
GB9718903D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO2000069390A2 (en) 1999-05-17 2000-11-23 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs
RU2236226C2 (ru) * 1999-06-18 2004-09-20 Бейкер Нортон Фармасьютикалз, Инк. Пероральные фармацевтические композиции, содержащие таксаны, и способы лечения с их применением
PL354777A1 (en) * 1999-10-27 2004-02-23 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
MXPA03006404A (es) * 2001-01-18 2004-12-02 Upjohn Co Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada.
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
EP1623706A3 (en) * 2001-02-28 2006-02-22 Bristol-Myers Squibb Company Metronomic dosing of taxanes for inhibiting tumor growth
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
CA2569139A1 (en) * 2004-06-04 2005-12-22 Smithkline Beecham (Cork) Limited Lapatinib with letrozole for use in a treatment of breast cancer
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CN102803234A (zh) * 2009-06-02 2012-11-28 霓坎制药有限责任公司 用于治疗疾病的人甲酰基肽受体的拮抗作用
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
BR112023018826A2 (pt) * 2021-03-17 2024-03-12 Dompe Farm Spa Inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
JPH06504772A (ja) * 1990-12-18 1994-06-02 ザ　ウエルカム　ファウンデーション　リミテッド 抗癌剤の薬効を増強し抗多剤耐性を有する薬剤
DE69220037T2 (de) * 1991-01-11 1997-11-06 Laboratoires Glaxo S.A., Paris Acridinderivate
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
JP2986550B2 (ja) * 1994-07-26 1999-12-06 インデナ・ソシエタ・ペル・アチオニ 抗腫瘍活性を有する半合成タキサン
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US5916566A (en) * 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1997027855A1 (en) * 1996-01-31 1997-08-07 Bristol-Myers Squibb Company A method of making pharmaceutically active taxanes orally bioavailable
CA2258556A1 (en) * 1996-06-17 1997-12-24 Julian Stanley Kroin Drug resistance and multidrug resistance modulators
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
KR100661879B1 (ko) * 1998-04-01 2006-12-27 스키에파마 캐나다 인코포레이티드 항암 조성물

Also Published As

Publication number Publication date
BR9809694A (pt) 2000-10-03
AR012731A1 (es) 2000-11-08
UA74767C2 (en) 2006-02-15
DK0994706T3 (da) 2006-03-06
DE69832173D1 (de) 2005-12-08
EP0994706A1 (en) 2000-04-26
ES2247690T3 (es) 2006-03-01
CZ9904244A3 (cs) 2001-10-17
DE69832173T2 (de) 2006-08-03
KR100615783B1 (ko) 2006-08-25
WO1998053811A1 (en) 1998-12-03
NO995812D0 (no) 1999-11-26
KR20010013025A (ko) 2001-02-26
CN1550231A (zh) 2004-12-01
ZA984268B (en) 1999-06-23
CA2290446C (en) 2008-01-29
ATE308365T1 (de) 2005-11-15
HUP0003546A2 (hu) 2002-11-28
CN1261275A (zh) 2000-07-26
CA2290446A1 (en) 1998-12-03
AU7130098A (en) 1998-12-30
SK157599A3 (en) 2002-10-08
IL132992A0 (en) 2001-03-19
IL132992A (en) 2006-08-20
HK1026637A1 (en) 2000-12-22
EP0994706B1 (en) 2005-11-02
HUP0003546A3 (en) 2002-12-28
PL337064A1 (en) 2000-07-31
RU2205005C2 (ru) 2003-05-27
EP0994706A4 (en) 2001-05-16
JP2002500667A (ja) 2002-01-08

Similar Documents

Publication Publication Date Title
NO995812D0 (no) Metode og sammensetninger for administrering av taxaner oralt til pasienter
DK1079809T3 (da) Enterisk overtrukket farmaceutisk sammensætning og fremgangsmåde til fremstilling deraf
NO994778D0 (no) FremgangsmÕter og sammensetninger for behandling av tarmbetennelse
NO20016198D0 (no) Orale farmasöytiske sammensetninger som inneholder taxaner og fremgangsmåter for anvendelse av samme i behandling
IS2058B (is) Ný taxóíð, aðferð til framleiðslu þeirra og lyfjasamsetningar sem innihalda þau
NO20004741D0 (no) Farmasøytiske blandinger for forlenget peptidfrigjøring og fremstillingsmetode
IS5097A (is) Fenófíbrat lyfjasamsetning með háa lífeðlisfræðilega upptöku og aðferð til framleiðslu hennar
NO994757L (no) Fremgangsmåte for oral administrasjon av proteiner
DK0890359T3 (da) Beta-Lactam-antibiotikumholdige tabletter og fremgangsmåde til fremstilling deraf
NO20003051D0 (no) Metode for administrering av AspB28-humant insulin
IS5245A (is) Lyfjablanda úr ómeprasól
NO982311D0 (no) Sammensetninger og fremgangsmÕter for forhindring og behandling av oral mukositt
NO20010260D0 (no) Tarmbeskyttelsesbelagt farmasöytisk tablett og fremgangsmåte for fremstilling
NO984878D0 (no) Fremstilling og anvendelse som medikamenter av 3-alkoksypyridin-2-karboksylsyreamidestere
NO20002851D0 (no) Blandinger for nasal administrasjon av medikamenter
NO20005017L (no) Metoder og viskøse sammensetninger for behandling av brønner
NO20000932D0 (no) Farmasøytisk preparat for kombinasjon av piperidinoalkanol og dekongestant
IS4635A (is) 4-fenýlamínóþíasólafleiður, aðferð við að framleiða þær og lyfjablöndur sem innihalda þær
FI955310L (fi) Farmaseuttinen koostumus flavonoidien antamiseksi oraalisesti
EE200200105A (et) Radiofarmatseutilised saadused ja nende valmistamise meetod
DK1210119T3 (da) Farmaceutiske sammensætninger til oral og topisk administrering
NO20022008D0 (no) Fremgangsmåte og preparater for oral administrering av taxaner til humane pasienter
NO991613D0 (no) Farmas°ytiske mikrosfµrer av valpronsyre for oral administrering
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
NO995406D0 (no) Farmasöytiske sammensetninger av tizoksanid og nitazoksanid

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application